Nabla Bio is a Cambridge, Massachusetts-based startup that is raising $26 million in Series A investment to develop AI and wet-lab technology.
Investors
- AstraZeneca
- Bristol Myers Squibb Company
- Takeda
- Radical Ventures
Use of funds
The money will be used by the business to increase operations and development initiatives.
Nabla works with pharmaceutical firms who have experience in drug development to fill their pipelines with high-quality drug candidates that address some of the most difficult, high-impact targets in order to optimize the platform’s impact on patients.
In addition to providing insightful information on disease biology and platform development, these partnerships cover a substantial amount of R&D costs, allowing Nabla to expand rapidly and sustainably.
About Nabla Bio
Under the direction of Surge Biswas and Frances Anastassacos, Nabla Bio creates wet-lab and integrated AI technologies that allow for high-throughput drug function measurement and atomically precise drug design. Initially, the company focused on developing antibodies that target multipass membrane proteins, such as transporters, ion channels, and G protein-coupled receptors (GPCRs).
